NI201200176A - Derivados de 3, 4 - dihidropirrolo [ 1, 2 - a] pirazina - 2, 8 (1h) - dicarboxamida su preparación y su uso terapéutico. - Google Patents
Derivados de 3, 4 - dihidropirrolo [ 1, 2 - a] pirazina - 2, 8 (1h) - dicarboxamida su preparación y su uso terapéutico.Info
- Publication number
- NI201200176A NI201200176A NI201200176A NI201200176A NI201200176A NI 201200176 A NI201200176 A NI 201200176A NI 201200176 A NI201200176 A NI 201200176A NI 201200176 A NI201200176 A NI 201200176A NI 201200176 A NI201200176 A NI 201200176A
- Authority
- NI
- Nicaragua
- Prior art keywords
- alkyl
- cycloalkyl
- group
- therapeutic use
- hydroxy
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 abstract 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 abstract 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Compuestos que responden a la fórmula general (I) en la que R2 representa un grupo alquilo - C1-10, cicloalquilo - C3-10, cicloalquil - C3-7 - alquilo - C1-6, alquilo - C1-6 - cicloalquilo - C3-7, cicloalquil - C3-7 - cicloalquilo - C3-7, alquiltio - C1-6 - alquilo - C1-10, alcoxi - C1-6 - alquilo - C1-10, hidroxi - alquilo - C1-10, hidroxi - alquil - C1-6 - cicloalquil - C3-7 -alquilo - C1-6, hidroxi - cicloalquilo - C3-10, fluoroalquilo - C1-10, fluorocicloalquilo - C3-10; un grupo heterocíclico sustituido opcionalmente; un grupo alquilo - C1-10 sustituido con un grupo heterocíclico sustituido opcionalmente; X6 representa un grupo elegido entre el átomo de hidrógeno, de flúor, de cloro o de bromo o un grupo alquilo C1-6, cicloalquilo - C3 7, cicloalquil - C3-7 - alquilo - C1-6, fluoroalquilo - C1-6 o ciano; y R7 representa un grupo arilo tal como fenilo o naftilo, sustituidos opcionalmente con uno o varios sustituyentes en el estado de base o de sal de adición a un ácido. Uso terapéutico.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1054372A FR2960876B1 (fr) | 2010-06-03 | 2010-06-03 | Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201200176A true NI201200176A (es) | 2013-02-06 |
Family
ID=42697541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201200176A NI201200176A (es) | 2010-06-03 | 2012-11-30 | Derivados de 3, 4 - dihidropirrolo [ 1, 2 - a] pirazina - 2, 8 (1h) - dicarboxamida su preparación y su uso terapéutico. |
Country Status (39)
| Country | Link |
|---|---|
| US (2) | US8791119B2 (es) |
| EP (1) | EP2588480B1 (es) |
| JP (1) | JP5995841B2 (es) |
| KR (1) | KR20130113928A (es) |
| CN (1) | CN103168041B (es) |
| AR (1) | AR081832A1 (es) |
| AU (1) | AU2011268651B2 (es) |
| BR (1) | BR112012030697A2 (es) |
| CA (1) | CA2801154C (es) |
| CL (1) | CL2012003360A1 (es) |
| CO (1) | CO6602113A2 (es) |
| CR (1) | CR20120595A (es) |
| CY (1) | CY1118512T1 (es) |
| DK (1) | DK2588480T3 (es) |
| DO (1) | DOP2012000296A (es) |
| EA (1) | EA201291364A1 (es) |
| EC (1) | ECSP12012322A (es) |
| ES (1) | ES2603420T3 (es) |
| FR (1) | FR2960876B1 (es) |
| GT (1) | GT201200319A (es) |
| HR (1) | HRP20161494T1 (es) |
| HU (1) | HUE030650T2 (es) |
| IL (1) | IL223364A (es) |
| LT (1) | LT2588480T (es) |
| MA (1) | MA34360B1 (es) |
| MX (1) | MX2012014084A (es) |
| NI (1) | NI201200176A (es) |
| NZ (1) | NZ603947A (es) |
| PE (1) | PE20130259A1 (es) |
| PH (1) | PH12012502353A1 (es) |
| PL (1) | PL2588480T3 (es) |
| PT (1) | PT2588480T (es) |
| SG (1) | SG186143A1 (es) |
| SI (1) | SI2588480T1 (es) |
| TN (1) | TN2012000520A1 (es) |
| TW (1) | TWI487707B (es) |
| UY (1) | UY33428A (es) |
| WO (1) | WO2011161537A2 (es) |
| ZA (1) | ZA201209071B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2960876B1 (fr) * | 2010-06-03 | 2012-07-27 | Sanofi Aventis | Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique. |
| AR098414A1 (es) | 2013-11-14 | 2016-05-26 | Bristol Myers Squibb Co | PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e |
| JP6307989B2 (ja) * | 2014-04-02 | 2018-04-11 | 住友化学株式会社 | 塩、酸発生剤、レジスト組成物及びレジストパターンの製造方法 |
| CN110709523B (zh) * | 2017-04-12 | 2023-07-11 | 豪夫迈·罗氏有限公司 | 使用经pictet spengler反应获得的加标签的核苷的测序反应方法 |
| US11247998B2 (en) * | 2017-07-27 | 2022-02-15 | Jiangsu Hengrui Medicine Co., Ltd. | Piperazine heteroaryl derivative, preparation method therefor and use of same in medicine |
| CN119451964A (zh) * | 2022-06-29 | 2025-02-14 | 英矽智能科技知识产权有限公司 | Fgfr2和fgfr3抑制剂及其用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU778870B2 (en) | 1999-02-01 | 2004-12-23 | University Of Virginia Patent Foundation | Compositions for treating inflammatory response |
| PL369530A1 (en) * | 2001-09-19 | 2005-05-02 | Aventis Pharma S.A. | Chemical compounds |
| GB0202015D0 (en) * | 2002-01-29 | 2002-03-13 | Hoffmann La Roche | Piperazine Derivatives |
| CN100439367C (zh) | 2003-12-11 | 2008-12-03 | 安万特药物公司 | 作为酪蛋白激酶Iε抑制剂的取代的1H-吡咯并[3,2-b、3,2-c和2,3-c]吡啶-2-甲酰胺以及相关类似物 |
| GB0328900D0 (en) | 2003-12-12 | 2004-01-14 | Glaxo Group Ltd | Novel compounds |
| US8304408B2 (en) * | 2007-05-24 | 2012-11-06 | The Regents Of The University Of California | Wnt signaling inhibitors, and methods for making and using them |
| BRPI0813094A2 (pt) * | 2007-07-27 | 2014-12-23 | Sanofi Aventis | Derivados de 1,2,3,4-tetra-hidro pirrolo (1,2-a) pirazina-6-carboxamidas e de 2,3,4,5-tetra hidro pirrolo (1,2-a) (1,4)-diazepina-7-carboxamidas, o respectivo preparo e a respectiva aplicação em terapêutica. |
| JP2011509961A (ja) * | 2008-01-17 | 2011-03-31 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 置換スルホンアミド誘導体 |
| WO2009097515A2 (en) * | 2008-01-30 | 2009-08-06 | Wyeth | [a]-fused indole compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses |
| FR2960876B1 (fr) * | 2010-06-03 | 2012-07-27 | Sanofi Aventis | Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique. |
-
2010
- 2010-06-03 FR FR1054372A patent/FR2960876B1/fr not_active Expired - Fee Related
-
2011
- 2011-06-01 PT PT117815902T patent/PT2588480T/pt unknown
- 2011-06-01 PL PL11781590T patent/PL2588480T3/pl unknown
- 2011-06-01 BR BR112012030697A patent/BR112012030697A2/pt not_active IP Right Cessation
- 2011-06-01 CN CN201180038277.8A patent/CN103168041B/zh not_active Expired - Fee Related
- 2011-06-01 EP EP11781590.2A patent/EP2588480B1/en active Active
- 2011-06-01 PE PE2012002257A patent/PE20130259A1/es not_active Application Discontinuation
- 2011-06-01 SI SI201131022A patent/SI2588480T1/sl unknown
- 2011-06-01 WO PCT/IB2011/001594 patent/WO2011161537A2/en active Application Filing
- 2011-06-01 LT LTEP11781590.2T patent/LT2588480T/lt unknown
- 2011-06-01 KR KR1020127031424A patent/KR20130113928A/ko active Search and Examination
- 2011-06-01 PH PH1/2012/502353A patent/PH12012502353A1/en unknown
- 2011-06-01 JP JP2013513006A patent/JP5995841B2/ja not_active Expired - Fee Related
- 2011-06-01 AU AU2011268651A patent/AU2011268651B2/en not_active Ceased
- 2011-06-01 DK DK11781590.2T patent/DK2588480T3/en active
- 2011-06-01 EA EA201291364A patent/EA201291364A1/ru unknown
- 2011-06-01 SG SG2012088795A patent/SG186143A1/en unknown
- 2011-06-01 NZ NZ603947A patent/NZ603947A/en not_active IP Right Cessation
- 2011-06-01 MA MA35524A patent/MA34360B1/fr unknown
- 2011-06-01 HU HUE11781590A patent/HUE030650T2/en unknown
- 2011-06-01 MX MX2012014084A patent/MX2012014084A/es active IP Right Grant
- 2011-06-01 CA CA2801154A patent/CA2801154C/en not_active Expired - Fee Related
- 2011-06-01 ES ES11781590.2T patent/ES2603420T3/es active Active
- 2011-06-02 AR ARP110101901A patent/AR081832A1/es not_active Application Discontinuation
- 2011-06-03 TW TW100119696A patent/TWI487707B/zh not_active IP Right Cessation
- 2011-06-03 UY UY0001033428A patent/UY33428A/es unknown
-
2012
- 2012-10-31 TN TNP2012000520A patent/TN2012000520A1/en unknown
- 2012-11-22 DO DO2012000296A patent/DOP2012000296A/es unknown
- 2012-11-26 CR CR20120595A patent/CR20120595A/es unknown
- 2012-11-27 GT GT201200319A patent/GT201200319A/es unknown
- 2012-11-29 IL IL223364A patent/IL223364A/en not_active IP Right Cessation
- 2012-11-29 US US13/688,916 patent/US8791119B2/en not_active Expired - Fee Related
- 2012-11-30 NI NI201200176A patent/NI201200176A/es unknown
- 2012-11-30 CL CL2012003360A patent/CL2012003360A1/es unknown
- 2012-11-30 ZA ZA2012/09071A patent/ZA201209071B/en unknown
- 2012-12-03 CO CO12218640A patent/CO6602113A2/es active IP Right Grant
- 2012-12-03 EC ECSP12012322 patent/ECSP12012322A/es unknown
-
2014
- 2014-07-23 US US14/339,112 patent/US9233965B2/en not_active Expired - Fee Related
-
2016
- 2016-11-11 HR HRP20161494TT patent/HRP20161494T1/hr unknown
- 2016-11-16 CY CY20161101179T patent/CY1118512T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201200176A (es) | Derivados de 3, 4 - dihidropirrolo [ 1, 2 - a] pirazina - 2, 8 (1h) - dicarboxamida su preparación y su uso terapéutico. | |
| PE20161405A1 (es) | Analogos de cortistatina y sintesis y usos de los mismos | |
| PE20190656A1 (es) | Compuestos de tiazolo-piridina sustituida como inhibidores de malt1 | |
| CO6592042A2 (es) | Derivados de n3-sustituido -n1-sulfonil-5-fluorpirimidinona | |
| ES2531274T3 (es) | Indazoles sustituidos con oxazol como inhibidores de PI3-cinasas | |
| MX2015003538A (es) | Derivados de 3-fenilisoxazolina con accion herbicida. | |
| AR094911A1 (es) | SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO ASÍ COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARÍNICO M₃ | |
| AR098912A1 (es) | Inhibidores de syk | |
| CO6491116A2 (es) | Derivados de 5-fluoropirimidinona | |
| ES2600636T3 (es) | Spiro-[1,3]-oxazinas y spiro-[1,4]-oxazepinas como inhibidores de BACE1 y/o BACE2 | |
| PE20080524A1 (es) | DERIVADOS DE 1H-IMIDAZO[4,5-b]PIRAZIN Y COMPOSICIONES FARMACEUTICAS QUE LOS COMPRENDEN | |
| UY32631A (es) | Derivados de ciclopenta[c]pirrol-2-carboxilatos, su preparación y su aplicación en terapéutica. | |
| CR20150254A (es) | Compuestos quimicos | |
| ES2601956T3 (es) | Composición para batería de litio que comprende al menos un compuesto de flúor específico como disolvente orgánico y al menos una sal de litio | |
| CO6362007A2 (es) | Derivados de azaspiranil-alquilcarbamatos de heterociclos de 5 eslabones, su preparación y su aplicación en terapeútica | |
| UY35229A (es) | Compuestos de diona cíclica herbicidas, derivados de los mismos, métodos de control de malezas y composiciones de los mismos | |
| CR20120033A (es) | Derivados de 5-fluoro-2-oxopirimidina-1-(2h) carboxilato. | |
| ECSP12011652A (es) | Derivados de 5-fluoro-2-oxopirimidinona-1 (2h)-carboxamida substituida-n1 | |
| AR083301A1 (es) | Uso de composiciones de halogeno organico para reducir las emisiones de mercurio durante la combustion de carbon | |
| UY32632A (es) | Derivados de ciclopenta[c]pirrolilalquilcarbamatos de heterociclos de 5 miembros, su preparación y su aplicación en terapéutica. | |
| MX2016003422A (es) | Imidazo[1,2-a]piridina-7-aminas como herramientas de imagen. | |
| UY32246A (es) | Derivados de carbamatos de alquil-heterociclos, su preparación y su aplicación en terapéutica | |
| AR070074A1 (es) | Derivados 6- heterociclico- imidazo ( 1,2-alfa) piridina -2- carboxamidas, su preparacion y su aplicacion en terapeutica | |
| ES2546833T3 (es) | Derivados de pirrolidina como antagonistas de receptores de NK-3 | |
| AR077395A1 (es) | Derivados de 2- 1,2 -bencisoxazol-3-il ) bencilamina |